Merck using video detailing to expand marketing efforts, cut costs

Share this article:
Merck has expanded its marketing efforts into video detailing as part of its new commercial model, global human health president Peter Loescher said. “We have seen video detailing over the past 10 years…We have created a state of the art video service for physicians who want to communicate with us in this way. There is (already) very good segmentation under way.” Loescher told investors during a meeting at Merck’s Whitehouse Station, NJ, headquarters last week. Merck’s video detailing efforts aim to serve as a cost-effective way to interact with large physician offices, rather than through large sales forces, Loescher said. “We have identified targets. We have scaled this up to 50,000 physician offices. Theses physicians want to communicate with us, so this is a critical moment,” he said. In addition to saving money, Loescher reported that video detailing had increased the quality of average physician interactions. He said, while the average call by a sales rep lasts 4.5 minutes, video detailing has increased interaction time by 10%. Merck began pilot testing the new video detailing model in 2006 with the launches of human papilloma virus vaccine Gardasil and Type 2 diabetes treatment Januvia. Merck expects “significant cost effectiveness with this new means of communication,” Loescher said. Merck estimates put the average cost of a traditional sales rep detail to specialists at $120 and to primary care physicians at $50. In comparison, Merck estimates the cost per video detail to be about $40. Loescher said Merck does not plan to increase the size of its sales force, despite the recent launches of Gardasil and Januvia. “Overall we will keep the head count structure flat.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...